All questionsReal-world evidence: Dupixent (dupilumab) in atopic dermatitis3 questions · 1 sourceReal-world evidenceWhat itch results has Dupixent shown in real-world use (PROSE registry)?“PROSE (12+ YEARS) CHANGE FROM BASELINE1 73% mean improvement in Peak Pruritus NRS score Mean Peak Pruritus NRS score was 7.1 at baseline (n=622) and 1.9 at 3 years (n=135) COMPLETE/NEAR-COMPLETE RESPONSE2 56% proportion of patients achieving Peak Pruritus NRS score of 0/1 At baseline, 2.7% of patients had Peak Pruritus NRS score of 0/1 (n=622) vs 56% at 3 years (n=103)” (opens the source at this quote in a new tab)CopyFlag“PROSE: PROSE is an ongoing, longitudinal, prospective, observational registry in the USA and Canada (NCT03428646) of patients aged ≥12 years with moderate-to-severe AD, treated with DUPIXENT in accordance with approved prescribing information (N=857; data presented include 55 adolescents aged ≥12 to <18 years). Data presented here are from an interim analysis. Limitations of analysis: Patients were also treated with other AD medications. While the initial prescription for DUPIXENT had to be in accordance with approved prescribing information, physicians were free thereafter to make any treatment decisions they deemed appropriate. Also, there could be a bias toward better outcomes in patients who continue providing data in this real-world study.1,2” (opens the source at this quote in a new tab)CopyFlagWhat skin improvement has Dupixent shown at 4 years of real-world use?“Real-world results in skin improvement at 4 years” (opens the source at this quote in a new tab)CopyFlag“98% EASI-75 86% EASI-90” (opens the source at this quote in a new tab)CopyFlag“RETROSPECTIVE DYNAMIC COHORT STUDY: In this retrospective, multicenter, Italian dynamic cohort study, data on 2576 adult patients with moderate-to-severe AD treated with DUPIXENT were collected from 24 dermatological centers from June 2018 to July 2022. Data are from patients observed at 4 months (N=2364), 12 months (N=2066), 24 months (N=1291), 36 months (N=601), and 48 months (N=110). Limitations of analysis: Limitations include the retrospective nature of the study and dynamic cohort design that hindered considerations regarding drug survival. Patients were also treated with other AD medications. Also, there could be a bias toward better outcomes in patients who continue providing data in the real-world study.3” (opens the source at this quote in a new tab)CopyFlagHow many patients stay on Dupixent long term for atopic dermatitis (real-world persistence)?“RELIEVE-AD STUDY (18+ YEARS) AT 5 YEARS4 74% of patients treated with DUPIXENT remained on therapya At Month 60, 26% of patients had discontinued therapy with DUPIXENT IBM MARKETSCAN (18+ YEARS) AT 1 YEAR5 77% of adult patients treated with DUPIXENT remained on therapy” (opens the source at this quote in a new tab)CopyFlag“RELIEVE-AD: RELIEVE-AD is a single-arm, prospective, observational study in patients with moderate-to-severe AD enrolled in DUPIXENT MyWay® prior to initiating treatment with DUPIXENT. Patients completed multiple surveys over 60 months. At Month 60, participants that responded to the survey at Month 33 and/or Month 48 were recontacted for Month 60 follow-up. Limitations of analysis: This patient population was self-selected; those who maintain long-term efficacy and safety may be more likely to participate in such surveys. Similarly, patients were recruited through a DUPIXENT patient support program, which may influence patient perceptions of treatment benefit.4,6 IBM MARKETSCAN: From IBM MarketScan Commercial and Medicare supplemental databases, 1963 adults were identified who initiated DUPIXENT between March 28, 2017, and March 31, 2018, and followed until September 30, 2018, or disenrollment. Patients received a mean of 8.6 DUPIXENT dispensations from initiation to first discontinuation. Limitations of analysis: Kaplan-Meier analysis was used to estimate persistence at 6 and 12 months, assuming a 14-day injection frequency. Limitations of this study may be the potential misclassification of patients in claims-based analyses that rely on International Classification of Disease (ICD) diagnostic codes for population identification. Study included only early initiators of DUPIXENT, which likely reflects more severe patients, potentially reducing generalizability since persistence may be different in a more diverse population of patients who initiate DUPIXENT. Duration of treatment and persistence was based on assumptions about whether and how patients take their treatment, and such assumptions may result in misclassification that could potentially over- or underestimate persistence.5” (opens the source at this quote in a new tab)CopyFlag“Percentages calculated as total patients who permanently discontinued DUPIXENT from Month 1 up until each month subtracted from the number of patients that started treatment at baseline (N=471). From Month 1 through Month 60, 122 patients permanently discontinued DUPIXENT. In addition, 39 patients discontinued DUPIXENT and restarted at a later time point at least once.” (opens the source at this quote in a new tab)CopyFlag